Systemic therapy for recurrent, persistent, or metastatic cervical cancer: a clinical practice guideline

Current Oncology

M. Fung Kee Fung³  L. Elit²  E.B. Kennedy⁴  H. Hirte¹ 

[1] Juravinski Cancer Centre;Juravinski Cancer Centre and McMaster University;University of Ottawa;Program in Evidence-based Care

关键词: cervical cancer;    systemic therapy;    chemotherapy;    systematic review;    practice guideline;   

DOI  :  

学科分类：肿瘤学

来源: Multimed, Inc.

【 摘 要 】

BackgroundSystemic therapy options are needed for women with recurrent, metastatic, or persistent cervical cancer. This systematic review and clinical practice guideline were developed to address that need, and to update a 2007 guideline from Cancer Care Ontario’s Program in Evidence-Based Care. MethodsThe literature between 2006 and April 2014 in the medline and embase databases, the Cochrane Database of Systematic Reviews (Issue 4, 2014), the Cochrane Central Register of Controlled Trials (Issue 3, 2014), relevant guideline databases, and conference proceedings of the American Society of Clinical Oncology (2007–2013) was searched. A working group developed draft guidelines and incorporated comments and feedback from internal and external reviewers. ResultsFour phase iii randomized controlled trials met the inclusion criteria for the review and provided the basis for draft recommendations. Feedback was obtained from Ontario practitioners and others abroad, which led to modifications to the draft recommendations. Three key recommendations were developed. ConclusionsThe working group concluded that all patients should be offered the opportunity to participate in appropriate randomized clinical trials. Cisplatin–paclitaxel, cisplatin–vinorelbine, cisplatin–gemcitabine, and cisplatin–topotecan are recommended combinations for this patient population. The substitution of carboplatin for cisplatin in the foregoing combinations can also be recommended because carboplatin is associated with fewer adverse effects and greater ease of administration. Selection of combination chemotherapy will depend on the toxicity profile, patient preference, and other factors. Finally, bevacizumab in combination with cisplatin–paclitaxel or carboplatin–paclitaxel is recommended for a specific subset of the target population as outlined in Gynecologic Oncology Group study 0240.

【 授权许可】

Unknown